LONDON
Technavio has published a new report on the osteoporosis drugs market in BRIC nations, which is expected to grow at a CAGR of over 17% from 2015-2019.
About the Report
According to the new report by Technavio, an overall assessment of the advantages and disadvantages of current osteoporosis treatment options presents the existence of unmet medical needs for the available drugs.
“Unmet medical need in terms of safety, efficacy, and compliance compels researchers to develop drugs that increase bone density, replace lost bone mass, and rebuild bone strength. For instance, Pfizer will likely lead the market during the forecast period through the sales of bazedoxifene, a third generation selective estrogen receptor modulator,” says Faisal Ghaus, Vice President of Technavio.
The latest report by Technavio also emphasizes the shift toward anabolic treatment, which are currently in the late and mid-stages of development.
“The treatment paradigm of osteoporosis has been stationary for the past few decades in the BRIC countries. Therefore, the launch of new efficacious and safe anabolic treatments will be the major modification in the management of osteoporosis,” adds Ghaus.
Market Scope and Calculation of Market Size
The new Technavio report covers the present scenario and growth prospects of the osteoporosis drugs market in BRIC nations from 2015-2019. To calculate the market size, we consider revenue generated from the sales of various branded and generic pharmaceutical products for treating osteoporosis.
Key Information Covered in the Report:
- Key Vendors:
- Amgen
- Eli Lilly
- Merck
- Novartis
- Market Growth Drivers:
- Rise in aging population
- For a full detailed list, view our report.
- Market Challenges:
- Expiry of patents
- For a full detailed list, view our report.
- Market Trends:
- Shift toward anabolic treatment
- For a full detailed list, view our report.
Technavio currently has more than 3000 market research reports on a huge range of topics, including 100+ reports on the osteoporosis drugs market:
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151007005045/en/
CONTACT
Technavio Research
Jesse Maida
US: +1-630-333-9501
UK:
+44-208-123-1770
Media & Marketing Executive
www.technavio.com
media@technavio.com
